Gamma Secretase Market -Pipeline Review, H2 2017

“The Latest Research Report Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

About Gamma Secretase Market

Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2017, outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request For Sample Report @

Gamma Secretase (EC 3.4.23.)-Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer’s disease patients. Gamma secretase is also critical in the related processing of the Notch protein. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 11 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Ear Nose Throat Disorders which include indications Alzheimer’s Disease, Hearing Disorders, Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Brain Cancer, Burkitt Lymphoma, Glioblastoma Multiforme (GBM), Leukemias, Medulloblastoma, Metastatic Breast Cancer, Soft Tissue Sarcoma, Solid Tumor and T-Cell Leukemia.

Furthermore, this report also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

View Sample PDF @


– The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)

– The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects

– The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Have Any Query? Ask Our Expert @

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Gamma Secretase (EC 3.4.23.)-Overview 7

Gamma Secretase (EC 3.4.23.)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 14

Gamma Secretase (EC 3.4.23.)-Therapeutics Assessment 16

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Gamma Secretase (EC 3.4.23.)-Companies Involved in Therapeutics Development 22

Astellas Pharma Inc 22

Bristol-Myers Squibb Co 22

Critical Outcome Technologies Inc 22

Lipopharma Therapeutics SL 23

Merck & Co Inc 23

NeuroGenetic Pharmaceuticals Inc 24

Pfizer Inc 24

Stemline Therapeutics Inc 25

Takeda Pharmaceutical Co Ltd 25

Gamma Secretase (EC 3.4.23.)-Drug Profiles 27

AS-2715348-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

BMS-932481-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

BMS-986133-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

GSI-34-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

LP-226A1-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

LY-3056480-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

NGP-328-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

NGP-555-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

nirogacestat-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Peptides to Inhibit PSEN1 for Alzheimers Disease-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

PF-06648671-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SL-301-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SL-302-Drug Profile 42

Product Description 42

Mechanism Of Action 42

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074



Designed by
Powered by
%d bloggers like this: